Physician profile

Lien N Trinh

Pediatric Endocrinology · Orange, CA

NPI 1518082304

$2,700.58

in general payments reported to CMS, 2019-2025

34 companies · $572 in 2025

The $572 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).

See the full distribution for Pediatric Endocrinology

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,269.28

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Neurocrine Biosciences, INC. $371.94 2023-2025
Abbvie INC. $244.34 2019-2025 Lupron Depot
Ascendis Pharma Endocrinology INC $215.80 2022-2024
Dexcom, INC. $169.11 2019-2024 Dexcom G6 Transmitter
Novo Nordisk INC $151.05 2019-2025 Sogroya
Tandem Diabetes Care, INC. $144.84 2019-2025 T:Slim X2 Insulin Pump With Control-Iq
Ipsen Biopharmaceuticals, INC $110.46 2019-2020
Insulet Corporation $103.85 2019-2025 Omnipod
Rhythm Pharmaceuticals, INC. $99.30 2021-2023 Imcivree
Lilly USA, LLC $96.05 2019-2020
Biomarin Pharmaceutical INC. $82.50 2022
Arbor Pharmaceuticals, INC. $80.41 2019-2022
Eton Pharmaceuticals, INC. $76.37 2023-2025 Alkindi, Khindivi, Increlex
Medtronic, INC. $76.08 2023 Mycarelink, Inpen Smart Insulin Delivery System
Pfizer INC. $55.50 2022-2025
Show all 34 companies
CompanyGeneral paymentsYearsTop products
Horizon Therapeutics Plc $53.27 2019-2020
Abbott Laboratories $53.10 2019-2021
Beta Bionics, INC. $52.64 2023-2025 Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset
Medtronic Minimed, INC. $49.88 2019-2020
Alexion Pharmaceuticals, INC. $45.81 2019
Becton, Dickinson and Company $41.96 2022
Azurity Pharmaceuticals, INC. $38.93 2023-2025 Triptodur, Triptodur
Tolmar Pharmaceuticals, INC. $38.14 2022
Embecta Corp. $29.22 2023 Bd Nano 2nd Gen Pen Needle
Zealand Pharma US, INC. $29.18 2021
Companion Medical, INC. $26.34 2020
Sanofi-Aventis U.S. LLC $24.94 2024
Ultragenyx Pharmaceutical INC. $24.46 2022
Kyowa Kirin, INC. $24.27 2025
Endo Pharmaceuticals INC. $23.26 2022
Vistapharm, INC. $20.70 2021
Genzyme Corporation $18.23 2019
Amphastar Pharmaceuticals, INC. $17.24 2024
Aegerion Pharmaceuticals, INC. $11.41 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$115,522.21 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Lien N Trinh

$2,700.58

in general payments reported 2019-2025

Years
2019-2025
Top company
Neurocrine Biosciences, INC.
Context
The $572 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).

https://glasscript.com/doctor/340323/lien-n-trinh

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.